What is the recommended treatment for a 76-year-old patient with multiple myeloma harboring del(17p) and an Eastern Cooperative Oncology Group (ECOG) performance status of 2?

Treatment Recommendation for 76-Year-Old with del(17p) Multiple Myeloma and ECOG 2

For this 76-year-old patient with del(17p) multiple myeloma and ECOG performance status of 2, initiate a triplet regimen combining a proteasome inhibitor (bortezomib or carfilzomib), lenalidomide, and dexamethasone, followed by continuous maintenance therapy. 1, 2

Rationale for Aggressive Triplet Therapy Despite Age and Performance Status

The del(17p) cytogenetic abnormality represents one of the highest-risk features in multiple myeloma, and ECOG 2 status is often reversible with effective disease control 3. Recent case series demonstrate that patients presenting with ECOG 4 (bedbound) can recover to ECOG 2 or better with aggressive multi-agent therapy, achieving functional independence within a median of 10 weeks 3. Your patient at ECOG 2 has substantially better baseline function and should tolerate intensive therapy.

Specific Regimen Selection

First-Line Options (in order of preference):

1. Daratumumab + Lenalidomide + Dexamethasone (D-Rd)

• Network meta-analysis identified this as the best treatment option for relapsed disease 2
• While primarily studied in relapse, the combination of anti-CD38 monoclonal antibody with immunomodulatory therapy addresses high-risk cytogenetics

2. Carfilzomib + Lenalidomide + Dexamethasone (KRd)

• Most compelling data for del(17p): Median PFS of 24.5 months in relapsed/refractory del(17p) patients 4
• Carfilzomib combined with lenalidomide maintained efficacy across high-risk and standard-risk patients (23 vs 29 months, P=NS) 1
• Superior to lenalidomide-dexamethasone alone in high-risk cytogenetics

3. Bortezomib + Lenalidomide + Dexamethasone (VRd)

• Bortezomib-based therapy with maintenance significantly improves outcomes in del(17p) 1, 5
• Chinese cohort showed median OS "not reachable" with bortezomib vs 10.8 months without bortezomib (P=0.017) 5
• PAD induction followed by bortezomib maintenance achieved PFS of 25.7 months vs 12-14.6 months without bortezomib 4

Critical Treatment Principles

Why Triplets Over Doublets:

• All three best-treatment options are triple-combination regimens for high-risk disease 2
• Meta-analysis confirms combined therapy with second-generation proteasome inhibitors, monoclonal antibodies, and immunomodulatory drugs improves outcomes in del(17p) 2, 4
• Doublet therapy (lenalidomide-dexamethasone alone) shows inferior results: PFS only 2-14.9 months in del(17p) patients 4

Maintenance Therapy is Non-Negotiable:

• Continuous lenalidomide maintenance partially overcomes del(17p) poor prognosis (29 vs 14 months) 1
• Bortezomib maintenance specifically improves prognosis in newly diagnosed del(17p) patients 4, 5
• Do not stop therapy at fixed timepoint—continue until progression or intolerance

Autologous Stem Cell Transplantation Consideration

Collect stem cells early but defer transplant decision based on response depth:

• Age 76 with ECOG 2 makes transplant feasibility uncertain but not impossible 6
• Real-world data show median PFS of 19.9 months and OS of 71.5 months with upfront auto-HCT in del(17p) 7
• Achieving MRD-negative complete response post-induction predicts better outcomes (HR 0.35 for PFS) 7
• If patient achieves ≥VGPR with triplet therapy and improves to ECOG 0-1, consider intermediate-dose melphalan conditioning 6

Monitoring and Response Assessment

Assess response after 4 cycles:

• Target: ≥VGPR (very good partial response)
• Obtain MRD testing if achieving ≥VGPR—MRD-negative status is the strongest predictor of improved PFS 7
• If achieving MRD-negative ≥VGPR without transplant, continue maintenance indefinitely

Common Pitfalls to Avoid

1. Do not use doublet therapy (e.g., lenalidomide-dexamethasone alone)—insufficient for del(17p) 4
2. Do not withhold intensive therapy based solely on age or ECOG 2—functional status often improves with disease control 3
3. Do not stop maintenance therapy prematurely—continuous therapy partially abrogates del(17p) adverse prognosis 1
4. Do not rely on radiotherapy for soft tissue plasmacytomas if present—these patients show poor response to radiation 5

Additional High-Risk Features to Assess

Check for concurrent cytogenetic abnormalities:

• t(4;14) + del(17p) = ultra-high-risk: Median PFS only 11.5 months and OS 22.4 months even with transplant 7
• 1q21 gain co-occurs in 23% of del(17p) cases 5
• If double-hit abnormalities present, consider clinical trial enrollment for novel agents

Age-Specific Dose Modifications

At age 76, anticipate need for:

• Reduced dexamethasone dosing (20 mg weekly rather than 40 mg)
• Carfilzomib: start 20/36 mg/m² rather than 20/56 mg/m² if cardiac comorbidities
• Lenalidomide: dose-adjust for renal function (common in elderly MM patients)
• Bortezomib: subcutaneous administration reduces neuropathy risk